Astatine-211 (At-211) is a promising alpha emitting radioisotope for cancer therapy, but its short 7.2-hour half-life means that it must be handled quickly to minimize losses due to radioactive decay. In this research, scientists designed and tested an automated device for producing At-211 that improves production time and efficiency. The device also minimizes the dose of radioactivity to production staff and reduces the time needed to prepare samples for shipment.
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
